caa a22 4500 469073950 CHVBK 20180323132929.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF01741143 doi (NATIONALLICENCE)springer-10.1007/BF01741143 Significant antitumor effect of a synthetic lipid A analogue, DT-5461, on murine syngeneic tumor models [Elektronische Daten] [Eiji Kumazawa, Akiko Tohgo, Tsunehiko Soga, Tsuneo Kusama, Yasuaki Osada] Summary: The antitumor effect of a synthetic lipid A analogue, DT-5461, was investigated using syngeneic tumor models in mice. Intravenous injection of DT-5461 into mice transplanted with solid tumors of MethA fibrosarcoma, MH134 hepatoma, MM46 mammary carcinoma, Lewis lung carcinoma (3LL), and colon adenocarcinomas 26 and 38 resulted in significant reductions in the weight of all tumors except Colon 26, with marked hemorrhagic necrosis of tumor tissues. Efficacy was almost equal to that of anEscherichia coli-type synthetic lipid A (compound 506), and also to those of some chemotherapeutics including Adriamycin, mitomycin C, fluorouracil and cisplatin. Furthermore, DT-5461 was more effective than other immunotherapeutics, including picibanil (OK-432) and lentinan. However, its antitumor effects were inferior to those of Adriamycin or OK-432 against the malignant ascites caused by intraperitoneal inoculation with MethA or with MH134 cells; life span was not prolonged by either intraperitoneal or intravenous administration. In addition, although DT-5461 showed direct inhibitory effects on the in vitro growth of MethA or MH134, these were much weaker than those of Adriamycin. These findings clearly indicated that DT-5461 with systemic administration is a highly effective antitumor agent on solid tumors, and suggest that the antitumor effect of DT-5461 with potent necrotizing activity might derive from indirect mechanisms related to the activation of host immune systems and not to the weak direct cytotoxicity. Springer-Verlag, 1992 DT-5461 nationallicence Lipid A nationallicence Murine syngeneic tumors nationallicence Antitumor effect nationallicence Kumazawa Eiji Exploratory Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., 16-13, Kita-Kasai 1-chome, Edogawa-ku, 134, Tokyo, Japan aut Tohgo Akiko Exploratory Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., 16-13, Kita-Kasai 1-chome, Edogawa-ku, 134, Tokyo, Japan aut Soga Tsunehiko Exploratory Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., 16-13, Kita-Kasai 1-chome, Edogawa-ku, 134, Tokyo, Japan aut Kusama Tsuneo Exploratory Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., 16-13, Kita-Kasai 1-chome, Edogawa-ku, 134, Tokyo, Japan aut Osada Yasuaki Exploratory Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., 16-13, Kita-Kasai 1-chome, Edogawa-ku, 134, Tokyo, Japan aut Cancer Immunology, Immunotherapy Springer-Verlag 35/5(1992-09-01), 307-314 0340-7004 35:5<307 1992 35 262 https://doi.org/10.1007/BF01741143 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741143 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kumazawa Eiji Exploratory Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., 16-13, Kita-Kasai 1-chome, Edogawa-ku, 134, Tokyo, Japan aut NATIONALLICENCE 700 1- Tohgo Akiko Exploratory Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., 16-13, Kita-Kasai 1-chome, Edogawa-ku, 134, Tokyo, Japan aut NATIONALLICENCE 700 1- Soga Tsunehiko Exploratory Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., 16-13, Kita-Kasai 1-chome, Edogawa-ku, 134, Tokyo, Japan aut NATIONALLICENCE 700 1- Kusama Tsuneo Exploratory Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., 16-13, Kita-Kasai 1-chome, Edogawa-ku, 134, Tokyo, Japan aut NATIONALLICENCE 700 1- Osada Yasuaki Exploratory Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., 16-13, Kita-Kasai 1-chome, Edogawa-ku, 134, Tokyo, Japan aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/5(1992-09-01), 307-314 0340-7004 35:5<307 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer